# Safety Study of CTS21166 to Treat Alzheimer Disease

> **NCT00621010** · PHASE1 · COMPLETED · sponsor: **CoMentis** · enrollment: 56 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** CTS21166 (ZPQ-21166)

## Key facts

- **NCT ID:** NCT00621010
- **Lead sponsor:** CoMentis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2008-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621010, "Safety Study of CTS21166 to Treat Alzheimer Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00621010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*